SB1518 for Patients With Myelodysplastic Syndrome (MDS)
Status:
Terminated
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if SB1518 can help to control
myelodysplastic syndrome. The safety of the drug will also be studied.
SB1518 is designed to block JAK2 and FLT3. SB1518 may have anti-tumor activity in certain
leukemias, myelofibrosis, and lymphoma.